Amneal Pharmaceuticals, Inc. (AMRX) stock
AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3063% above fair value
$21.12−0.11 (-0.52%)
Close on Nov 17, 2026Market cap $6.74BP/E 43.1Yield –
Amneal Pharmaceuticals operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Amneal Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was $200.78M, down 42.8% year over year. For fiscal 2025 it was $339.99M, up 15.2% from the year before. The highest annual figure on record is $379.00M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $339.99M | +15.2% |
| FY2024 | Dec 31, 2024 | $295.10M | -14.6% |
| FY2023 | Dec 31, 2023 | $345.58M | +430.8% |
| FY2022 | Dec 31, 2022 | $65.10M | -73.1% |
| FY2021 | Dec 31, 2021 | $241.82M | -36.2% |
| FY2020 | Dec 31, 2020 | $379.00M | +22128.8% |
| FY2019 | Dec 31, 2019 | $1.71M | -99.3% |
| FY2018 | Dec 31, 2018 | $250.23M | +6.9% |
| FY2017 | Dec 31, 2017 | $234.19M | +103.5% |
| FY2016 | Dec 31, 2016 | $115.06M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$21.24M | -125.3% |
| Q1 FY2026 | Mar 31, 2026 | -$26.74M | -461.0% |
| Q4 FY2025 | Dec 31, 2025 | $130.32M | +10.4% |
| Q3 FY2025 | Sep 30, 2025 | $118.45M | -16.5% |
| Q2 FY2025 | Jun 30, 2025 | $83.82M | +111.4% |
| Q1 FY2025 | Mar 31, 2025 | $7.41M | – |
| Q4 FY2024 | Dec 31, 2024 | $118.08M | -13.1% |
| Q3 FY2024 | Sep 30, 2024 | $141.77M | +74.2% |
| Q2 FY2024 | Jun 30, 2024 | $39.66M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.41M | -103.2% |
| Q4 FY2023 | Dec 31, 2023 | $135.82M | – |
| Q3 FY2023 | Sep 30, 2023 | $81.39M | -13.0% |
| Q2 FY2023 | Jun 30, 2023 | -$11.35M | – |
| Q1 FY2023 | Mar 31, 2023 | $139.71M | +16.1% |
| Q4 FY2022 | Dec 31, 2022 | -$23.29M | -136.8% |
| Q3 FY2022 | Sep 30, 2022 | $93.57M | +13.6% |
| Q2 FY2022 | Jun 30, 2022 | -$125.52M | – |
| Q1 FY2022 | Mar 31, 2022 | $120.34M | -18.8% |
| Q4 FY2021 | Dec 31, 2021 | $63.26M | -40.3% |
| Q3 FY2021 | Sep 30, 2021 | $82.36M | +83.9% |
| Q2 FY2021 | Jun 30, 2021 | -$51.93M | -129.0% |
| Q1 FY2021 | Mar 31, 2021 | $148.13M | +202.1% |
| Q4 FY2020 | Dec 31, 2020 | $105.96M | – |
| Q3 FY2020 | Sep 30, 2020 | $44.78M | -68.0% |
| Q2 FY2020 | Jun 30, 2020 | $179.24M | +749.7% |
| Q1 FY2020 | Mar 31, 2020 | $49.03M | – |
| Q4 FY2019 | Dec 31, 2019 | -$50.89M | -119.6% |
| Q3 FY2019 | Sep 30, 2019 | $139.91M | +125.2% |
| Q2 FY2019 | Jun 30, 2019 | $21.09M | – |
| Q1 FY2019 | Mar 31, 2019 | -$108.41M | -501.1% |
| Q4 FY2018 | Dec 31, 2018 | $259.65M | – |
| Q3 FY2018 | Sep 30, 2018 | $62.13M | -15.5% |
| Q2 FY2018 | Jun 30, 2018 | -$98.58M | – |
| Q1 FY2018 | Mar 31, 2018 | $27.03M | – |
| Q4 FY2017 | Dec 31, 2017 | $0 | – |
| Q3 FY2017 | Sep 30, 2017 | $73.51M | – |
See a number that looks wrong?